Literature DB >> 31411751

Computed tomography performance in predicting extranodal extension in HPV-positive oropharynx cancer.

Farhoud Faraji1, Nafi Aygun2, Stephanie F Coquia2, Christine G Gourin3, Marietta Tan3, Lisa M Rooper4, David W Eisele3, Carole Fakhry3,5,6.   

Abstract

OBJECTIVES: To evaluate the performance characteristics of seven predetermined imaging features on pretreatment computed tomography (CT) in identifying extranodal extension (ENE) in cervical lymph node metastases from human papillomavirus-positive oropharyngeal carcinoma (HPV-OPC). STUDY
DESIGN: Retrospective study.
METHODS: Seventy-three patients with HPV-OPC who underwent primary surgery and cervical lymph node dissection were included. Preoperative contrast-enhanced CT (cCT) imaging was evaluated by two radiologists blinded to pathological results. Each cCT was scored for seven imaging features of interest: 1) indistinct capsular contours, 2) irregular nodal margins, 3) perinodal fat stranding, 4) perinodal fat planes, 5) nodal necrosis, 6) intranodal cysts, and 7) nodal matting. Logistic regression was employed to determine radiologist-specific odds ratios (OR) of predicting ENE for each imaging feature and radiologist-specific receiver operating characteristics (sensitivity [Sn], specificity [Sp], area under the curve [AUC], positive predictive value [PPV], negative predictive value [NPV]) for each imaging feature.
RESULTS: Thirty-two (44%) patients had ENE-positive lymph nodes. The presence of irregular margins (ORA = 12.3, 95% confidence interval [CI]A = 2.3-65.9; ORB = 7.0, 95% CIB = 1.4-36.3) and absence of perinodal fat plane (ORA = 6.8, 95% CIA = 2.0-23.3; ORB = 14.2, 95% CIB = 1.7-120.5) were significantly associated with ENE for each radiologist. Irregular nodal margin status was most specific for ENE (SnA = 45%, SpA = 94%, AUCA = 69%, PPVA = 82%, NPVA = 73%; SnB = 28%, SpB = 95%, AUCB = 61%, PPVB = 80%, NPVB = 64%). Absence of perinodal fat plane was most sensitive for ENE (SnA = 87%, SpA = 50%, AUCA = 69%, PPVA = 59%, NPVA = 62%; SnB = 96%, SpB = 34%, AUCB = 65%, PPVB = 53%, NPVB = 63%).
CONCLUSIONS: Of the seven imaging features hypothesized to be associated with ENE-status, the presence of irregular nodal margins and absence of perinodal fat plane were the most specific and sensitive features, respectively. LEVEL OF EVIDENCE: 4 Laryngoscope, 130:1479-1486, 2020.
© 2019 The American Laryngological, Rhinological and Otological Society, Inc.

Entities:  

Keywords:  HPV; Oropharynx; computed tomography; extranodal extension; squamous cell carcinoma

Mesh:

Year:  2019        PMID: 31411751     DOI: 10.1002/lary.28237

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  3 in total

Review 1.  Advances in Imaging for HPV-Related Oropharyngeal Cancer: Applications to Radiation Oncology.

Authors:  Travis C Salzillo; Nicolette Taku; Kareem A Wahid; Brigid A McDonald; Jarey Wang; Lisanne V van Dijk; Jillian M Rigert; Abdallah S R Mohamed; Jihong Wang; Stephen Y Lai; Clifton D Fuller
Journal:  Semin Radiat Oncol       Date:  2021-10       Impact factor: 5.421

2.  Accuracy of the Anatomage Table in detecting extranodal extension in head and neck cancer: a pilot study.

Authors:  Giancarlo Tirelli; Jasmina de Groodt; Egidio Sia; Manuel Gianvalerio Belgrano; Ferruccio Degrassi; Paolo Boscolo-Rizzo; Maria Assunta Cova; Alberto Vito Marcuzzo
Journal:  J Med Imaging (Bellingham)       Date:  2021-02-01

3.  Prognostic Value of Radiological Extranodal Extension Detected by Computed Tomography for Predicting Outcomes in Patients With Locally Advanced Head and Neck Squamous Cell Cancer Treated With Radical Concurrent Chemoradiotherapy.

Authors:  Abhishek Mahajan; Ankur Chand; Ujjwal Agarwal; Vijay Patil; Richa Vaish; Vanita Noronha; Amit Joshi; Akhil Kapoor; Nilesh Sable; Ankita Ahuja; Shreya Shukla; Nandini Menon; Jai Prakash Agarwal; Sarbani Ghosh Laskar; Anil D' Cruz; Pankaj Chaturvedi; Devendra Chaukar; P S Pai; Gouri Pantvaidya; Shivakumar Thiagarajan; Swapnil Rane; Kumar Prabhash
Journal:  Front Oncol       Date:  2022-05-27       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.